Last reviewed · How we verify
Ho Cheol Shin, M.D., Ph.D. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| GCJBP Laennec Inj. | GCJBP Laennec Inj. | phase 3 | Placental extract | Regenerative Medicine / General Health |
Therapeutic area mix
- Regenerative Medicine / General Health · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Ho Cheol Shin, M.D., Ph.D.:
- Ho Cheol Shin, M.D., Ph.D. pipeline updates — RSS
- Ho Cheol Shin, M.D., Ph.D. pipeline updates — Atom
- Ho Cheol Shin, M.D., Ph.D. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Ho Cheol Shin, M.D., Ph.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ho-cheol-shin-m-d-ph-d. Accessed 2026-05-17.